I-AIkido Pharma Inc. namhlanje ichaze ukuphuculwa kwenkqubo yokuvelisa ichiza layo lomhlaza we-pancreatic, i-DHA-dFdC, ilayisensi evela kwiYunivesithi yaseTexas e-Austin. Inkampani ikwanike ingxelo yokukhutshwa kwelungelo elilodwa lomenzi wechiza elongezelelweyo lase-US eligquma ichiza, kunye nokufakwa kwesicelo esiqhubekayo selungelo elilodwa lomenzi wechiza ngenjongo yokwandisa ukugqunywa kwelungelo elilodwa lomenzi wechiza kwezinye iinkalo zechiza.
Ngokubhekiselele kwinkqubo yokwenziwa kwemveliso, iNkampani inike ingxelo ngophuhliso oluyimpumelelo lwendlela entsha yokuvelisa kunye nokwahlulwa kwekhompawundi engundoqo ephakathi ekwenzeni i-DH-dFdC. Inkampani ngoku yenze enye ikhontrakthi nombutho wayo wokwenza ikhontrakthi, iParimer Scientific, ukusebenzisa inkqubo entsha yokuvelisa amawaka eemiligram zechiza ukuze zisetyenziswe kuphuhliso loqulunqo kunye nezifundo zozinzo. Inkampani ikwanike ingxelo yokuba i-Ofisi yePatent yase-US isandula kukhupha iPatent entsha yase-US enguNombolo 11,219,633, ebonelela ngokhuseleko olongezelelweyo lwepropathi enomgangatho ophezulu wokuqonda kwikhompawundi yechiza. Ixesha lelungelo elilodwa lomenzi wechiza kulindeleke ukuba liqhubeke kude kube nguMeyi ka-2035 kunye nentlawulo efunekayo yokulondoloza. Ngaphambi kokukhutshwa kwelungelo elilodwa lomenzi wechiza, iNkampani yagunyazisa ukufakwa kwangethuba kwesicelo sokuqhubekeka kwelungelo elilodwa lomenzi wechiza, Uthotho lwe-US No.
U-Anthony Hayes, i-CEO ye-AIkido, uthe, "Le nkqubo intsha inyathelo elibalulekileyo eliya phambili kuphuhliso lwechiza lethu lomhlaza wepancreatic kwaye kufuneka livumele ukuveliswa kwechiza kwinqanaba lezorhwebo ngexabiso eliphantsi. Ndikwavuyiswa kukuba singaqhubeka nokunika ingxelo ngokwandiswa kwepatent estate.”
URichard T. Pace, uMnini noNzululwazi oyiNtloko weParimer Scientific, uthe, “Indlela yokwenziwa kwemveliso entsha linyathelo elikhulu eliya phambili kobu buchwepheshe buvelisa izinto ezintsha. Ndiyakholelwa ukuba iya kunciphisa iindleko zeyunithi kwaye kwangaxeshanye inyuse umthamo wemveliso yebhetshi. ”
INTO ONOKUYITHATHA KWELI NQAKU:
- With respect to manufacturing process, the Company reported the successful development of a new means for the scaled production and isolation of the key intermediate compound in the manufacture of DH-dFdC.
- Anthony Hayes, CEO of AIkido, stated, “This new process significant step forward in the development of our pancreatic cancer drug and should permit production of the drug on a commercial scale at a lower cost.
- The Company has now executed a further contract with its contract manufacturing organization, Parimer Scientific, to employ the new process to produce several thousand milligrams of the drug for use in formulation development and stability studies.
